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Deep venous thrombosis and its sequelae remain
significant medical problems today. We have pre-
viously demonstrated a significant relationship
between the thrombotic process and inflamma-
tion,1,2 with inflammation amplifying the thrombot-
ic response. Importantly, we have found that inflam-
matory inhibition with recombinant interleukin-10
(IL-10) or with an antibody to P-selectin decreased
thrombosis.3,4
This study tested the hypothesis that the inhibi-
tion of the unique, mucin-like glycoprotein
expressed on the surface of most hematopoietic
cells, P-selectin glycoprotein-1 (PSGL-1), with high
affinity for P-selectin and lesser affinity for E-selectin
and L-selectin, will decrease both inflammation and
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Objective: This study was performed to determine the effectiveness of recombinant P-
selectin glycoprotein ligand Ig (rPSGL-Ig) pretreatment to decrease thrombosis and
inflammation in experimental venous thrombosis. rPSGL-Ig, a unique mucin-like gly-
coprotein, has a high affinity for P-selectin.
Methods: Twelve juvenile baboons underwent inferior vena cava (IVC) thrombosis with
temporary 6-hour IVC balloon occlusion. Before balloon placement, the animals
received rPSGL-Ig (4 mg/kg; n = 8) or saline solution for control (n = 4). The animals
underwent evaluation with duplex ultrasound scan imaging, magnetic resonance venog-
raphy (MRV), phlebography, coagulation profile, and tissue analysis at death for
cytokines and vein wall leukocyte morphometrics. With the MRV results, thrombus
development, thrombus resolution, and inflammation (gadolinium; square millimeters
of enhancement) were assessed.
Results: Each animal provided two time points for evaluation (days 2 and 6 after balloon
occlusion). A significant decrease in IVC thrombosis between balloons was found in the
rPSGL-Ig animals (1 of 16) versus the control animals (5 of 8; P < .01). The MRV results
showed significantly less enhancement in the rPSGL-Ig animals at days 2 and 6 (P < .05).
Spontaneous thrombus resolution (including balloon sites) was significantly greater from
day 2 to day 6 in the rPSGL-Ig animals versus the control animals (23% vs 2%; P < .001),
without pulmonary embolism. Lower interleukin-8, platelet factor IV, and monocyte
chemotactic protein-1 levels were found in rPSGL-Ig vein walls without significant dif-
ferences in vein wall leukocyte morphometrics. There were significantly lower D-dimer
levels in the rPSGL-Ig-treated animals (P < .05), but there were no differences in mea-
surements of coagulation. Adequate circulating rPSGL-Ig levels were documented.
Conclusion: Pretreatment with rPSGL-Ig results in: (1) a significant inhibition of
thrombosis and vein wall inflammation; (2) a decrease in vein wall cytokine expression;
and (3) a promotion of thrombus resolution. Inflammatory inhibition by rPSGL-Ig
without anticoagulation therapy provides effective venous thrombosis prophylaxis in
experimental venous thrombosis. (J Vasc Surg 2000;31:309-24.)
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thrombosis during venous thrombosis. The binding
of PSGL-1 to P-selectin promotes the rolling and
tethering of leukocytes onto activated platelets and
activated endothelial cells, and the binding of PSGL-
1 to L-selectin facilitates the binding of leukocytes
to leukocytes and of leukocytes to the vessel wall.5
MATERIALS AND METHODS
Model. Twelve juvenile baboons (mean weight,
6.2 kg) made up this study. The primates underwent
initial anesthesia with 5 to 10 mg/kg of intramuscu-
lar Telazol (100 mg/mL; Elkins-Sinn, Inc, Cherry
Hill, NJ) that was supplemented with 0.3 mL intra-
venous Pentothal barbiturate (2.5% solution;
Abbott, North Chicago, Ill) before inhalation anes-
thesia with isoflurane (1% to 1.5%; AErrane, Fort
Dodge Animal Health, Fort Dodge, Iowa) and
100% oxygen. The animals underwent right groin
and neck venous cutdowns, followed by the inser-
tion of 6F silicon balloon catheters (Medi-Tech,
Boston Scientific Corporation, Watertown, Mass)
into the right femoral vein and the right internal
jugular vein. The catheters were placed with fluoro-
scopic guidance such that the proximal balloon was
positioned just below the level of the renal veins and
the distal balloon was situated at the iliac vein bifur-
cation of the inferior vena cava (IVC; Fig 1A). The
location of the renal vein and iliac bifurcation was
also identified with contrast phlebography. The
proximal cephalad balloon was inflated to 9 to 10
mm and was followed 60 seconds later by the distal
caudad balloon, which isolated an area of pure stasis
between the balloons. The position of the balloons
was confirmed with contrast phlebography and
venous duplex ultrasound scan imaging. For the
next 6 hours, the balloons were kept inflated, with
ultrasound scan examinations performed hourly to
confirm balloon positioning and to assure no pro-
grade flow into the IVC. At the completion of the 6-
hour occlusion interval, the balloons were deflated
and the catheters were removed without traversing
the mid IVC. Duplex ultrasound scan imaging
results defined the presence or the absence of
thrombus (Fig 1B). The femoral vein then was
repaired, and the jugular vein was ligated.
At baseline, approximately 1 hour before the cut-
downs were performed, eight animals received
recombinant P-selection glycoprotein ligand-Ig
(rPSGL-Ig; 4 mg/kg; Genetics Institute, Andover,
Mass) and four animals received saline solution for
control (Fig 2). The dose was chosen that com-
pletely binds cell-associated P-selectin and inhibits
P-selectin–mediated cellular interactions (Genetics
Institute data). Serum levels of rPSGL-Ig were
obtained in all animals with enzyme-linked
immunosorbent assay (ELISA). In addition, before
the cutdowns, all the baboons underwent baseline
venous duplex ultrasound scan imaging, magnetic
resonance venography (MRV), contrast phlebogra-
phy, full coagulation and hematologic profile, and
hemodynamic evaluation. All the animals underwent
a similar analysis (except for MRV) at the comple-
tion of the balloon occlusion interval, and with
MRV at day 2 (36 hours later) and at day 6. Four of
JOURNAL OF VASCULAR SURGERY
310 Wakefield et al February 2000
Fig 1. A, Note proximal and distal balloons, right renal vein (RRV) and left renal vein (LRV),
and area of mid inferior vena cava (IVC; arrow) between (B) gray-scale ultrasound scan image
showing thrombus (arrow) in mid IVC just after balloon removal in a control animal.
A B
the eight rPSGL-Ig-treated baboons were killed on
day 6, as were all the control animals, and four of the
eight rPSGL-Ig animals were followed out to day 30
after balloon occlusion. Just before death, the ani-
mals underwent evaluation with venous duplex
ultrasound scan imaging, MRV, contrast phlebogra-
phy, full coagulation profile, hemodynamics, and tis-
sue analysis for cytokines and vein wall leukocyte
content (morphometrics). The tissue analysis includ-
ed the entire IVC, the iliac veins, and a portion of
the superior vena cava, along with a thorough eval-
uation of the pulmonary arteries and suprarenal
IVC, for evidence of thrombus embolization.
Imaging. All the primates underwent phlebogra-
phy, MRV, and duplex ultrasound scan imaging.
Phlebography was performed at baseline, after balloon
inflation, after balloon deflation, at day 2, and at day 6.
A 22-gauge intravenous catheter was placed into the
saphenous vein in both calves, and 5 mL Hypaque dia-
trizoate meglumine (USP, 60%; Nycomed, Inc,
Princeton, NJ) was injected into both legs simultane-
ously. Phlebography was performed with a BV29 
C-arm fluoroscopy unit (Philips Medical System,
Cincinnati, Ohio).
The MRV studies were performed at baseline, at
day 2, and at day 6. These examinations used a 1.5-
T superconducting magnet (GE Medical Systems,
Milwaukee, Wis) and an extremity coil with 8.1 soft-
ware. The imaging sequences included time of flight
(TOF), inversion recovery (I/R), and T2-weighted
and T1-weighted pre-gadolinium and post-gadolin-
ium enhancement. Gadolinium (Gd) is a paramag-
netic heavy metal that shortens the T1 of adjacent
tissues and blood, producing increased signal, and is
administered in chelated form. Gadolinium is known
to extravasate selectively into areas of inflamma-
tion.4,6 An initial T1-weighted locator imaging was
performed in the coronal plane, whereas all subse-
quent imaging was performed in the axial plane. The
imaging began superior to the level of the renal veins
and extended down to the distal extent of the iliac
veins. The imaging parameters included: TOF (time
to repetition [TR], 47 ms; time to echo [TE], 9 ms;
flip angle, 60°), T2 (TR, 4000 ms; TE, 18 and 108
ms), I/R (TR, 4000 ms; TE, 36 ms; time to inver-
sion [TI], 150 ms), and T1 (TR, 300 ms; TE, 16
ms). Gadolinium-enhanced images were made after
the administration of gadopentetate dimeglumine
(0.4 mg/kg [0.2 mmol/kg]; Magnevist, Berlex
Labs, Wayne, NJ). The analysis for inflammation
involved the selection of regions of interest around
the IVC and the right iliac vein (RIV) at the location
of thrombus (not at balloon sites) or 20 cm above
and below the iliac vein bifurcation (if no thrombus
was present) and the measurement in square mil-
limeters of the amount of gadolinium enhancement
noted. I/R permitted the calculation of the bright
signal intensity (in square millimeters) of the vein
wall and perivenous tissue, reflecting edema at the
same locations. For these calculations, the areas at
the balloon sites were not included because of the
presumed injury of the vein wall by the balloons and
the effect of such localized injury on the MRV results.
For the determination of the amount of throm-
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 2 Wakefield et al 311
Fig 2. Experimental protocol. US, Ultrasound scanning; MRV, magnetic resonance venogra-
phy; rPSGL-Ig, recombinant P-selection glycoprotein ligand-Ig.
bus resolution between days 2 and 6, the TOF
images were used and the image with the most
thrombus was examined in each animal for both the
IVC and the RIV. The areas at the balloon sites were
allowed for this analysis, to have regions to evaluate
in the IVC in the rPSGL-Ig–treated animals. The
residual lumen was indexed against the vein as a
whole, resulting in a percent of residual lumen being
patent. The same image level was interrogated at day
2 and day 6 and was compared as the rate of change
over time. In two control animals in which throm-
bus migrated from day 2 to day 6 from the IVC
bifurcation to a level just inferior to the renal veins,
this calculation was excluded.
Duplex ultrasound scan imaging was performed
with a Toshiba Powervision 6000 (Toshiba Medical
Systems, Tustin, Calif). The probe size was 7.5
MHz, with the angle of insonation constant at 60°.
Compression color ultrasound scanning was per-
formed at baseline and then hourly during balloon
occlusion to document thrombus formation, contin-
uation of balloon occlusion, and maintenance of bal-
loon inflation, after balloon deflation, and at day 2
and day 6. In addition, the technique of tissue
Doppler imaging (TDI) was used for the detection
of thrombus. This technique derives signals from tis-
sue motion and bypasses the usual ultrasound scan
wall motion filter. Tissue motion is of low velocity,
low frequency, and high amplitude as compared with
blood. In most conventional ultrasound scans, these
low velocity signals are filtered out. With TDI, these
signals bypass the filter and are processed directly
into the autocorrelator of the imager, with the ampli-
tude of the Doppler scan signals autocorrelated to
the low frequency shift, eliminating blood flow sig-
nals.7 Thus, TDI shows velocity echoes from tissue
motion as distinct from the high velocity echoes of
flowing blood. In the case of venous thrombosis, the
tissue echoes correspond to thrombus (Fig 3). At
death, intraoperative direct imaging of the IVC and
the iliac veins was performed with an ATL Ultramark
3000 (Advanced Technologies Laboratory, Bothell,
Calif) and an intraoperative 10-MHz probe.
Gross analysis at death. At day 6, the animals
again underwent anesthesia and a laparotomy was
performed through a midline incision. Heparin sodi-
um, 1000 IU, was administered (Elkins-Sinn) just
before death to prevent the development of acute
thrombus during manipulation. With careful dissec-
tion, the IVC, the iliac veins, the suprarenal IVC, the
superior vena cava, and the pulmonary arteries were
examined for thrombus, and then the veins were
photographed. The tissues were subjected to histo-
logic evaluation, including proximal, mid, and distal
IVC (including balloon sites), right and left iliac
veins, superior vena cava, and any free thrombus not
attached to vein wall, including pulmonary emboli.
The specimens were sent for histologic analysis, mor-
phometrics, and cytokine analysis.
Histology and morphometrics. Leukocyte infil-
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Fig 3. Tissue Doppler scan imaging in (A) longitudinal and (B) transverse orientation on day
2 in a control animal. Yellow color of thrombus tail (wide arrows) indicates it is moving at dif-
ferent velocity than rest of thrombus in inferior vena cava (IVC). Smaller arrows and white line
indicate IVC wall. In an animal treated with recombinant P-selection glycoprotein ligand-Ig,
with tissue Doppler scan imaging in mid IVC in longitudinal orientation, no thrombus is noted
just after balloon removal (C) and on day 2 (D). Small arrows indicate IVC wall.
tration into the vein wall was evaluated with the mor-
phometric analysis of the mid IVC and the RIV areas.
Morphometrics were performed with the counting of
leukocytes in hematoxylin and eosin–stained seg-
ments of tissues.1 Each vein wall was assessed for the
subset and number of leukocytes in five randomly
selected high-power fields (1000×). These fields were
chosen at equidistant locations around the vein and
were chosen in the same fashion for all the baboons
to eliminate selection bias. The analysis began at the
thrombus-vein wall interface and extended the width
of 1 µm. With standard morphologic criteria, includ-
ing cell size, cytoplasmic content, and nuclear size,
the cells were identified as neutrophils, monocytes,
or lymphocytes. Cell identification has been previ-
ously validated with antibodies to neutrophils and
monocytes with immunohistochemical analysis.1 The
morphometric values of the IVC and the RIV were
computed and compared between groups.
In addition, the cellularity in the thrombus was
assessed on slides that were stained in a routine fash-
ion with hematoxylin and eosin. Any thrombus pre-
sent was analyzed, including thrombus at balloon
sites and at the RIV level. With an image analysis sys-
tem (Scion Corporation, Frederick, Md), the slides
were examined at 40× and the presence of inflam-
matory cells was indexed to total thrombus area.
The thrombus in each animal was measured, the
results then were presented as a ratio, and the two
groups were compared.
Cytokine analysis. ELISA allowed the quantifi-
cation of cytokines in vein wall tissue. Initial tissue
homogenization of the vein wall segments was per-
formed in a buffer that consisted of 1× phosphate-
buffered saline solution (PBS) with 2 mmol/L
phenylmethylsulfonyl fluoride and 1 µg/mL of each
of: pepstatin A, leupeptin, aprotinin, and antipan
(Sigma Chemical Co, St Louis, Mo). The suspension
was subsequently sonicated on ice for 30 seconds,
centrifuged at 1500g for 10 minutes, and filtered
through a 1.2-µm syringe filter. Immunoreactive
cytokine levels were quantified with specific ELISAs
as previously described.1 Flat-bottomed 96-well
microtiter plates were coated with 50 µL per well
with specific rabbit anticytokine antibody (ng/µL in
0.6 mol/L NaCl, 0.26 mol/L H3PO4, and 0.08 N
NaOH, pH 9.6) for 16 hours at 4°C and then
washed. Microtiter plate nonspecific binding sites
were blocked with 2% bovine serum albumin in PBS
and incubated for 60 minutes at 37°C. The plates
were washed three times, and diluted (1:5 and 1:10)
specimen (50 µL) in duplicate was added, followed
by incubation for 60 minutes at the same tempera-
ture. The plates were washed an additional three
times, followed by the addition of 50 µg per well 
of biotinylated rabbit anticytokine antibody (3.5
ng/µL in PBS, pH 7.5, 0.05% Tween-20, and 2%
fetal calf serum), and were incubated for 45 minutes
at 37°C. These secondary antibodies were specific for
the cytokine being tested, with no cross-reactiv-
ity to other cytokines found. Cytokines evaluat-
ed included the CXC chemokines interleukin 8
(IL-8) and platelet factor IV and the CC
chemokine monocyte chemotactic protein-1
(MCP-1). The plates were rewashed three times, 
followed by the addition of streptavidin-peroxi-
dase conjugate (1:5000, 100 µL per well; Bio-
Rad Laboratories), incubated for 30 minutes at
37°C, re-washed, and followed by the addition
of the chromogen substrate 3, 31, 5, 51 tetra-
methybenzidine (K and P Labs, Gaithersburg,
Md). The plates then were incubated at room
temperature to the desired extinction, terminat-
ing the reaction with 50 mL per well of 3 mol/L
H2PO4 solution. The plates were read at 450 nm
in an ELISA plate reader. Standards were 
1 ⁄2 log dilutions of the cytokines from 1 pg/mL to
100 ng/mL. The sensitivity of the ELISAs was
greater than or equal to 50 pg/ml. The values
were either corrected or not corrected to total
protein levels. The values in the IVC between
the balloons and the RIV were indexed to con-
trol left iliac vein values.
Coagulation and hematologic profile. The
coagulation and hematologic studies included acti-
vated partial thromboplastin time (aPTT) and
thrombin clotting times (TCT; Dade Diagnostics,
Miami, Fla) performed on a fibrometer (BBL Fibro-
system, Becton-Dickinson, Rutherford, NJ), tem-
plate bleeding times (Allegiance Health Care Corp,
McGaw Park, Ill), white blood cell counts and
platelet counts determined by hand hemocytometry
methods, and fibrinogen levels (Dade Diagnostics).
These levels were determined at baseline, after bal-
loon deflation, and at day 2 and day 6. Fibrin-split
products (Dade Diagnostics) and D-dimer levels
(Dade Diagnostics) were also determined at the
same time intervals.
Hemodynamics. Systemic arterial blood pres-
sure was measured hourly during the first experi-
mental day and at days 2 and 6, along with pulse rate
(Dynamap; Critikon, Tampa, Fla). A pulse oximeter
(Datascope; Accusat, Paramus, NJ) was used to
monitor systemic oxygen saturations, and intra-
venous fluids included 22 cc/kg/h during the first
experimental day.
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Statistical evaluation and animal use. Statis-
tical analysis included the mean ± the standard error
of the mean, unpaired Student t tests for parametric
data, Mann-Whitney tests for nonparametric data,
and linear regression. χ2 analysis or Fisher exact test
was used to analyze segments or animals whose test
results were positive for thrombus. Significance was
defined as P value of less than .05. All the baboons
were housed and cared for in the University of
Michigan Unit for Laboratory Animal Medicine
under the direction of a veterinarian according to
the “Principles of Laboratory Animal Care” (formu-
lated by the National Society for Medical Research)
and Guide for the Care and Use of Laboratory
Animals (NIH Publication No. 86-23, revised
1985). The protocol was approved by the University
of Michigan Committee on the Use and Care of
Animals (UCUCA, #6843A).
RESULTS
Thrombosis. The presence or the absence of
thrombus was assessed with a combination of MRV
TOF imaging results, duplex ultrasound scan imag-
ing results, and findings at death. Each animal had
two time points in which analysis was performed
after the first experimental day (days 2 and 6). Thus,
there were eight IVC segments to analyze in the
control animals and 16 in the treated animals.
Concerning segments, a significant decrease in
thrombosis was found in the IVC for the rPSGL-
Ig–treated animals (1 of 16; 6%) versus the control
animals (5 of 8; 63%; P < .01; Fig 4). At balloon sites
and in the RIV, a nonsignificant advantage for
rPSGL-Ig was also noted (balloon sites: rPSGL-Ig,
16 of 32 [50%], vs control, 12 of 16 [75%]; RIV:
rPSGL-Ig, 12 of 16 [75%], vs control, 8 of 8
[100%]). Concerning animals demonstrating throm-
bus at any time at day 2 or day 6, a strong trend
remained for the IVC in favor of the rPSGL-
Ig–treated primates (1 of 8; 13%) versus the control
primates (3 of 4; 75%) P = .067.
Inflammation and edema. Concerning inflam-
mation in the IVC as assessed with MRV with
gadolinium, less inflammation was noted in the
rPSGL-Ig–treated animals than in the control ani-
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Table I. Magnetic resonance venographic results
P 
rPSGL-Ig Control value
Gadolinium enhancement (mm2)
IVC
Base 2 ± 1 6 ± 2 NS
Day 2 9 ± 3 29 ± 11 <.05
Day 6 4 ± 2 38 ± 18 <.05
RIV
Base 2 ± 1 8 ± 3 <.05
Day 2 14 ± 4 28 ± 5 NS
Day 6 12 ± 4 24 ± 8 NS
IR bright signal (mm2)
IVC
Base 4 ± 2 4 ± 2 NS
Day 2 11 ± 5 41 ± 7 <.01
Day 6 3 ± 2 37 ± 17 <.01
RIV
Base 3 ± 2 1 ± 1 NS
Day 2 15 ± 8 30 ± 12 NS
Day 6 6 ± 4 14 ± 6 NS
rPSGL-Ig, Recombinant P-selectin glycoprotein ligand-Ig; IVC,
inferior vena cava; RIV, right iliac vein; IR, inversion recovery.
Fig 4. Percent of inferior vena cava (IVC) segments with positive results for thrombus at var-
ious locations. rPSGL-Ig, Recombinant P-selection glycoprotein ligand-Ig.
mals at day 2 (9 ± 3 vs 29 ± 11 mm2; P < .05) and
at day 6 (4 ± 2 vs 38 ± 18 mm2; P < .05; Table I).
Similar nonsignificant trends were noted for the RIV
at day 2 and at day 6 (Figs 5,6). Concerning edema
in the IVC as assessed with MRV with I/R, again
significantly less edema was noted in the rPSGL-
Ig–treated animals than in the control animals at day
2 (11 ± 5 vs 41 ± 7mm2; P < .01) and day 6 (3 ± 2
vs 37 ± 17; P < .01; Table I)]. Similar nonsignificant
trends were noted for the RIV at day 2 and day 6.
Thrombus resolution. Spontaneous thrombus
resolution was significantly greater from day 2 to day
6 in the rPSGL-Ig–treated animals versus the con-
trol animals (23 ± 2% increase in lumen opening [n
= 13] vs 2 ± 6% [n = 5]; P < .001) without evidence
of pulmonary embolism in any treated animal (Fig
7). One control animal demonstrated a large seg-
mental pulmonary embolus at death. The thrombus
resolution calculation took into account thrombus
noted on MRV TOF imaging in the IVC and RIV,
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Fig 5. With gadolinium-enhanced magnetic resonance imaging, note increased peri–inferior
vena cava (IVC) enhancement in a representative saline solution control as compared with a
representative recombinant P-selectin glycoprotein ligand-Ig (rPSGL-Ig), animal at day 2 (A).
Additional representative animals are shown at day 6 (B). In control animals, no T-1 short-
ened blood is present because of thrombus, and in animals treated with rPSGL-Ig, increased
signal is seen within slow-flowing blood. Note that despite presence of small amount of intra-
luminal thrombus in rPSGL-Ig–treated animal at day 2, no peri-IVC enhancement is seen.
A
B
including balloon sites, and was performed at the
point of maximum thrombus formation for both the
IVC and the RIV.
Cytokines and morphometrics. Concerning
vein wall cytokine levels, the values were indexed to
the healthy left iliac veins. Lower levels of IL-8,
platelet factor IV, and MCP-1 were found in the
rPSGL-Ig–treated vein walls, both noncorrected and
corrected to levels of total protein, as compared with
the control walls. Significant differences were noted
for IL-8 (RIV, noncorrected, P < .05), with near sig-
nificance for MCP-1 (IVC, noncorrected, P = .057;
RIV, noncorrected, P = .057; Table II). These
cytokine differences were found despite no significant
differences noted in vein wall morphometric data
(Table III). Of interest, linear regression comparing
MRV (gadolinium) and total inflammatory cells
revealed a significant correlation only for the mid IVC
in control animals (r = .99; r2=.98; P < .05).
Inflammatory cells in thrombus. The ratio of
inflammatory cells to total thrombus area was
reduced by 17% in those animals treated with rPSGL-
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Fig 6. With gadolinium-enhanced magnetic resonance imaging, note increased enhancement
around right iliac vein (RIV) thrombus in a representative saline solution control versus a rep-
resentative animal treated with recombinant P-selection glycoprotein ligand-Ig (rPSGL-Ig) at
day 2 (A) and day 6 (B). In the rPSGL-Ig animal at day 2, thrombus is noted, and at day 6,
a patent RIV is shown.
A
B
Ig as compared with the saline solution control ani-
mals (0.0100 ± 0.0048 vs 0.0121 ± 0.0024; NS).
Again, this calculation took into account any throm-
bus noted in the IVC, RIV, or balloon sites.
Coagulation and rPSGL-Ig levels. No differ-
ences were noted between groups in coagulation
profile, including aPTT and TCT (Table IV), leuko-
cyte counts (Table V), or platelet counts (Table VI),
except for a nonsignificant elevation in bleeding
time (day 2; Table VII) and a significant decrease in
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Fig 7. With time-of-flight magnetic resonance imaging, lumen opens up much more rapidly
over time in a representative animal treated with recombinant P-selection glycoprotein ligand-
Ig (rPSGL-Ig; A) as compared with a representative saline solution–treated control (B).
A
B
D-dimer presence in rPSGL-Ig–treated animals,
implying less thrombus burden (P < .05; Table
VIII). Levels of fibrinogen were also similar between
groups. Percent changes in platelet count (Fig 8)
and leukocyte count revealed a quicker return to
baseline for platelets and a greater rise in leukocyte
counts for rPSGL-Ig–treated animals. Adequate cir-
culating rPSGL-Ig levels were found for selectin
inhibition in all treated animals at all time points,
and no rPSGL-Ig was found in the control animals.
Levels of 109 ± 12 µg/mL at 6 hours after balloon
inflation, 60 ± 3 µg/mL at day 2, and 43 ± 5
µg/mL at day 6 were noted (effective concentra-
tions, 5 µg/mL or more [Genetics Institute data]).
Finally, no abnormalities in wound healing or infec-
tions were noted in any treated animal.
Long-term results. Four baboons survived past
day 6; all were treated with rPSGL-Ig and under-
went duplex scanning and MRV at day 30. In all
cases, the IVC and RIV appeared healthy, with only
the smallest piece of residual distal balloon site
thrombus in one of the four primates. No inflam-
mation or edema was noted with gadolinium admin-
istration in any of these primates at day 30 follow-up
examination.
DISCUSSION
We have previously demonstrated that the neu-
tralization of P-selectin in the same primate model
of venous thrombosis decreased vein wall inflamma-
tion and thrombus formation as compared with
saline solution control.3 In this study, we have
shown that a receptor antagonist for P-selectin and
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Table II. Cytokine ratio data
rPSGL-Ig Control P value
IVC/left iliac (non-
corrected to 
total protein)
IL-8 0.97 ± 0.35 2.23 ± 0.46 NS
PF-4 1.30 ± 0.41 1.77 ± 0.48 NS
MCP-1 1.24 ± 0.26 33.0 ± 18.4 NS (.057)
IVC/left iliac (cor-
rected to total 
protein)
IL-8 0.75 ± 0.18 1.38 ± 0.32 NS
PF-4 1.01 ± 0.21 1.16 ± 0.31 NS
MCP-1 1.38 ± 0.75 40.4 ± 24.5 NS
Right/left iliac 
(noncorrected 
to total protein)
IL-8 0.62 ± 0.09 2.60 ± 1.15 .029
PF-4 0.75 ± 0.12 1.32 ± 0.34 NS
MCP-1 4.2 ± 1.7 36.6 ± 19.2 NS (.057)
Right/left iliac 
(corrected to 
total protein)
IL-8 1.08 ± 0.18 1.66 ± 0.28 NS
PF-4 1.34 ± 0.28 1.14 ± 0.33 NS
MCP-1 6.8 ± 2.1 50.3 ± 26.2 NS
rPSGL-Ig, Recombinant P-selectin glycoprotein ligand-Ig; IVC,
inferior vena cava; IL-8, interleukin-8; PF-4, platelet factor IV;
MCP-1, monocyte chemotactic protein-1.
Table IV. Coagulation times
rPSGL-Ig Control P value
aPTT (seconds)
Base 28.8 ± 1.5 28.9 ± 2.4 NS
6 hours 37.4 ± 1.7 36.4 ± 2.0 NS
Day 2 36.4 ± 2.3 32.1 ± 1.0 NS
Day 6 27.9 ± 2.2 27.3 ± 1.7 NS
TCT (seconds)
Base 15.4 ± 0.6 16.3 ± 1.7 NS
6 hours 16.2 ± 0.8 15.0 ± 1.6 NS
Day 2 16.2 ± 0.5 15.6 ± 1.3 NS
Day 6 16.6 ± 0.7 16.0 ± 0.6 NS
rPSGL-IG, Recombinant P-selectin glycoprotein ligand-Ig;
aPTT, activated partial thromboplastin time; TCT, thrombin
clotting times.
Table III. Morphometrics (cells/5 high-power fields)
Monocytes Neutrophils Lymphocytes TCs
IVC
rPSGL-Ig 18 ± 2 10 ± 4 0 ± 0 28 ± 2
Control 20 ± 3 12 ± 5 1 ± 1 33 ± 5
P value NS NS NS NS
Right iliac
rPSGL-Ig 19 ± 2 30 ± 18 1 ± 1 50 ± 19
Control 21 ± 5 9 ± 3 0 ± 0 31 ± 5
P value NS NS NS NS
TC, Total inflammatory cells; IVC, inferior vena cava; rPSGL-Ig,
recombinant P-selectin glycoprotein ligand-Ig.
Table V. Leukocyte counts per cubic millimeter
rPSGL-Ig Control P value
Base 6,083 ± 371 8,663 ± 2,467 NS
6 hours 10,093 ± 1,527 10,038 ± 1,619 NS
Day 2 8,740 ± 752 7,013 ± 316 NS
Day 6 5,890 ± 320 5,390 ± 872 NS
rPSGL-IG, Recombinant P-selectin glycoprotein ligand-Ig.
Table VI. Platelet counts (×103) per cubic mil-
limeter
rPSGL-Ig Control P value
Base 281 ± 29 345 ± 72 NS
6 hours 209 ± 27 227 ± 26 NS
Day 2 242 ± 27 237 ± 29 NS
Day 6 314 ± 29 291 ± 42 NS
rPSGL-IG, Recombinant P-selectin glycoprotein ligand-Ig.
E-selectin, rPSGL-Ig, significantly decreased inflam-
mation and thrombus formation, while decreasing
levels of vein wall cytokines, especially in areas of
pure venous stasis. Importantly, rPSGL-Ig also pro-
moted thrombus resolution (without evidence for
pulmonary embolization) in areas in which clot did
form, such as in balloon sites and in the RIV.
Although there was no difference in vein wall
inflammatory cell extravasation between groups, the
primates treated with rPSGL-Ig revealed a decrease
in inflammatory cells noted in the thrombus.
P-selectin glycoprotein ligand-1 is the unique
glycoprotein, expressed by most hematopoietic cells,
with a high affinity for P-selectin and a lower affinity
for E-selectin and L-selectin. The truncation of the
receptor to its NH2-terminal 47 amino acids allows
for continuation of its high affinity for P-selectin with
less affinity for E-selectin and L-selectin. This NH2-
terminal 47 amino acid construct, linked to the Fc
portion of human immunoglobulin, along with a
change in two amino acids to alanine to disable the
Fc receptor binding and complement activation, is
the molecule studied in the present investigation,
recombinant P-selectin glycoprotein ligand-Ig
(rPSGL-Ig). It has a half life of approximately 15
days (Genetics Institute data).
The pharmacologic evaluation results of rPSGL-
Ig have revealed that it binds and inhibits cell-asso-
ciated P-selectin. Thrombin-activated platelets that
express P-selectin bind to neutrophils, and rPSGL-
Ig blocks this effect approximately 90% at very low
doses.8 In a similar fashion, platelet-leukocyte com-
plexes formed over de-endothelialized porcine
carotid artery are abolished by rPSGL-Ig at a con-
centration of 40 µg/mL.8 The binding of leukocytes
to thrombin-activated isolated feline coronary artery
endothelium is also inhibited by rPSGL-Ig, at 20
µg/mL.9
In different models of experimental injury,
rPSGL-Ig has been shown to decrease leukocyte-
mediated damage, including abdominal rotational
trauma in the rat,10 ischemia-reperfusion injury in
healthy and fatty rat livers,11 ischemia-reperfusion
injury in rat kidney transplants,12 and in rat and cat
myocardium.9,13 Importantly, rPSGL-Ig attenuated
the synergistic amplification of injury produced by
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Table VIII. D-dimer presence
rPSGL-Ig Control
Base 1/7 0/4
6 hours 2/8 2/4
Day 2 3/8 4/4
Day 6 4/8 4/4
rPSGL-Ig, Recombinant P-selectin glycoprotein ligand-Ig.
Combining 6 hours, day 2, and day 6 together, 9/24 vs 10/12, P
< .05.
Table VII. Bleeding times (minutes)
rPSGL-Ig Control P value
Base 1.56 ± 0.24 1.75 ± 0.32 NS
6 hours 2.50 ± 0.46 2.25 ± 0.43 NS
Day 2 3.06 ± 0.54 1.38 ± 0.32 NS (.063)
Day 6 2.21 ± 0.42 1.33 ± 0.33 NS
rPSGL-IG, Recombinant P-selectin glycoprotein ligand-Ig.
Fig 8. Percent changes in platelet counts between groups at 6 hours, at day 2, and at day 6.
rPSGL-Ig, Recombinant P-selection glycoprotein ligand-Ig
platelets and neutrophils.13 In the cat studies,
rPSGL-Ig given at 1 mg/kg was protective of both
myocardial ischemia/perfusion injury and vascular
endothelial function.9 The effect on traumatic shock
included not only an inhibition of leukocyte-
endothelial cell interactions but also an actual
decrease in the de novo synthesis of PSGL-1, as con-
firmed with messenger RNA quantification of
PSGL-1 blood cell levels.10 This additionally sug-
gests attenuation of leukocyte-leukocyte and leuko-
cyte-platelet interactions. This is important because
theoretically, activated neutrophils that have shed L-
selectin are still capable of interacting with flowing
neutrophils if the adherent neutrophils express
PSGL-1 and the flowing neutrophils express L-
selectin.14
In this study, inflammation as measured with
gadolinium enhancement on MRV was significantly
decreased in areas of pure venous stasis (mid IVC)
and was also decreased in the presence of the
catheter (RIV), with no change in vein wall leuko-
cyte extravasation. This result is similar to what was
found in our laboratory with the GA6 antibody to
P-selectin, an antibody directed against the terminal
portion of P-selectin.3 The finding that inflamma-
tion was reduced without a change in the number of
extravasated inflammatory cells suggests that the
extravasated cells were not activated to release sub-
stances that participate in inflammation, such as pro-
teases, eicosanoids, cytokines, and oxygen-free radi-
cals. In addition, the amount of edema noted in the
vein wall and perivenous tissue was less in those ani-
mals treated with rPSGL-Ig.
The fact that cytokine production was decreased
from the vein walls of rPSGL-Ig–treated animals is
similar to findings in ischemia/reperfusion injury in
the rat kidney transplant model.12 In this model,
selectin inhibition with rPSGL-Ig decreased a num-
ber of cytokines, including IL-2, interferon-γ,
RANTES (regulated upon activation, normal T cell
expressed and presumably secreted), IL-2R, IL-4,
IL-1, tumor necrosis factor–α (TNF-α), transform-
ing growth factor–β (TGF-β), and inducible nitric
oxide synthase. In addition, E-selectin expression
was inhibited. Because rPSGL-Ig has much more
activity against P-selectin than E-selectin or L-
selectin, this suggests that the inhibition of the local-
ized production of proinflammatory cytokines,
which induce adhesion molecule expression,15 may
be responsible for the protection from inflammation
noted many hours after P-selectin upregulation
would be expected to have normalized.10 We like-
wise noted a decrease in vein wall cytokines that was
similar to the present study in primates treated with
antibody to P-selectin.3
In a model of porcine thrombolysis, rPSGL-Ig
was found to accelerate thrombus lysis by 70% at
250 µg/kg and 61% at 500 µg/kg.16 This is similar
to results with antibody to P-selectin in which
thrombolysis was accelerated in models of vessel wall
injury.17 This is likely the result of a reduced fibrin
content of the thrombus, because platelet-leukocyte
interaction that leads to tissue factor release and sub-
sequent fibrin deposition have been found to be 
P-selectin dependent.16-19 In the present study,
thrombus resolution was significantly accelerated in
those animals treated with rPSGL-Ig, again support-
ing the previous studies. This suggests that forma-
tion and stabilization of the thrombus requires
endothelial-leukocyte-platelet interactions.
We noted no differences in coagulation and
hematologic studies in those animals administered
rPSGL-Ig as compared with control animals, with
the exception of a nonsignificant increase in bleed-
ing time at day 2 (1.56 ± 0.24 minutes to 3.06 ±
0.54 minutes) and a subjective assessment of in-
creased oozing at the time of balloon deflation. 
The usual normal range for bleeding time in our
primate experience is 1 minute to 3 minutes, with a
mean of 1.75 minutes. This is generally consistent 
with other studies in which rPSGL-Ig has been
found not to interfere with normal hemostasis and
platelet function (Robert Schaub, Genetics Institute,
written communication, December 1998) and not to
prolong bleeding time when used with heparin,
aspirin, or heparin/aspirin combinations (Robert
Schaub, Genetics Institute, written communication,
December 1998). In these studies, the dose of
rPSGL-Ig was 1 mg/kg. However, the dose used in
the current study, 4 mg/kg, is likely the reason for
the bleeding time increase at day 2 and will need to
be decreased to normalize the bleeding time changes
and to rectify the oozing noted. Dose-response stud-
ies will define the appropriate dose of rPSGL-Ig that
will not cause any bleeding time elevation and will
not lead to clinical oozing. The important fact that
the aPTT and TCT were not different between the
groups and that there was less of a decline and a faster
return in platelet count in the rPSGL-Ig animals as
compared with the control animals emphasizes that
the efficacy of rPSGL-Ig is independent of a systemic
state of anticoagulation.
We found no healing problems and no infec-
tions in the current study. This is consistent with
previous studies, which suggests that rPSGL-Ig
does not reduce resistance to bacterial infections
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(Robert Schaub, Genetics Institute, written com-
munication, December 1998). The single dose of
rPSGL-Ig given to the primates provided adequate
circulating levels for selectin inhibition for the dura-
tion of the experimental protocol.
A number of proposed mechanisms has been
forwarded for the effectiveness of P-selectin anti-
body to be protective in addition to prevention of
leukocyte (primarily neutrophil) emigration into tis-
sue. These include prevention of neutrophil adhe-
sion to activated platelets20,21; decrease in the
release of cathepsin G from activated neutrophils21;
inhibition of P-selectin expression on endothelial
cells and platelets decreasing platelet-platelet and
platelet-leukocyte adhesion21,22; down regulation
of protein kinese C activation from endothelial cells
and platelets23; inhibition of tissue factor expression
on monocytes24; inhibition of the upregulation of
the nuclear transcription factor Nf-κB25 important
for cytokine production; and antagonism of com-
plement activation.26 Because rPSGL-Ig was pro-
tective in the current study without a significant
change in morphometrics of the vein wall and by
virtue of the fact that rPSGL-Ig functions primarily
as an antagonist of P-selectin, it is likely that it func-
tions by one or a combination of the previously 
proposed mechanisms. In support of the impor-
tance of rPSGL-Ig inhibiting platelet P-selectin as a
major mechanism of action are recent studies in
hepatic ischemia/reperfusion.27,28 In this condi-
tion, there is vascular damage before acute neu-
trophil injury, which leads to platelet accumulation.
In these studies, neutrophil sinusoidal localization is
independent of P-selectin, yet interventions against 
P-selectin are beneficial. This suggests that anti–
P-selectin interventions are hepatoprotective be-
cause of inhibition of platelet accumulation rather
than the inhibition of neutrophil extravasation. In
addition, in other venous thrombosis models in the
rat and cat in studies performed independent of the
current study, rPSGL-Ig prevented clot formation
in a dose-dependent fashion, without inhibiting
inflammatory cell extravasation.29,30 This again
suggests a non–leukocyte mediated mechanism,
likely including platelet inhibition. Clearly, our data
support the concept of a decrease in cytokine pro-
duction from the vein wall and definitely show the
real decrease in thrombus formation in the presence
of rPSGL-Ig.
Finally, and importantly, the current model is
applicable to clinical deep venous thrombosis (DVT).
Most DVT form in areas of venous stasis, corre-
sponding to the area of the IVC between balloons.
Less frequently, direct vein wall damage, such as
noted at balloon sites and in the RIV, accompanies
stasis for the production of DVT (such as during hip
surgery or with trauma). rPSGL-Ig was most effec-
tive in the IVC between balloons and, thus, should
be effective in the most common clinical situations
for the development of DVT. However, there was a
trend even at the balloon sites and in the RIV in
favor of rPSGL-Ig over control, which suggests that
rPSGL-Ig would be effective in situations of direct
vein wall damage plus stasis. In future studies, low
non-anticoagulant doses of anticoagulants will be
combined with rPSGL-Ig, in an attempt to augment
its effectiveness in areas of direct vein wall damage.
The 15-day half life of rPSGL-Ig is particularly clin-
ically relevant because a prophylactic dose would be
expected to act not only during the period of maxi-
mal thrombotic risk (operative and perioperative
period) but also well into the postoperative period.
SUMMARY
In summary, rPSGL-Ig pretreatment in isolated
venous stasis resulted in the following: (1) inhibition of
thrombosis generation; (2) reduction in phlebitis and
edema; (3) decreased vein wall cytokines; and (4) more
rapid thrombus resolution. These changes occurred
despite the presence of inflammatory cell extravasation.
Inflammatory inhibition by rPSGL-Ig without antico-
agulation therapy provides effective venous thrombosis
prophylaxis in experimental venous thrombosis.
We thank the Toshiba Corporation for the use of the
Toshiba Powervision 6000 during the study and the assis-
tance of Tony Dillard, RVT.
REFERENCES
1. Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski
SK, Burdick MD, et al. Venous thrombosis-associated inflam-
mation and attenuation with neutralizing antibodies to
cytokines and adhesion molecules. Arterioscler Thromb Vasc
Biol 1995;15:258-68.
2. Wakefield TW, Greenfield LJ, Rolfe MW, DeLucia A III,
Strieter RM, Abrams GD, et al. Inflammatory and procoagu-
lant mediator interactions in an experimental baboon model
of venous thrombosis. Thromb Haemost 1993;69:164-72.
3. Downing LJ, Wakefield TW, Strieter RM, Prince MR, Londy
FJ, Fowlkes JB, et al. Anti-P-selectin antibody decreases
inflammation and thrombus formation in venous thrombosis.
J Vasc Surg 1997;25:816-28.
4. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Austin JC,
Hare BD, et al. Interleukin-10 regulates thrombus-induced
vein wall inflammation and thrombosis. J Immunol 1998;
161:1471-6.
5. McEver RP, Cummings RD. Role of PSGL-1 binding to
selectins in leukocyte recruitment. J Clin Invest 1997;100:
485-92.
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 2 Wakefield et al 321
6. Prince MR. Gadolinium-enhanced MR aortography.
Radiology 1994;191:155-64.
7. Drozdz J, Schon F, Nesser HJ, Erbel R. Tissue doppler
echocardiography—new promising method in cardiovascular
diagnosis. Essen, 09.08.94.
8. Theoret JF, Kumar A, Latour J-G, Merhi Y. Mechanisms of
platelet binding to neutrophils in contact with damaged arte-
rial surfaces under flow conditions. Circulation 1998;98:I-
241,1251.
9. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM.
Recombinant soluble P-selectin glycoprotein ligand-1 pro-
tects against myocardial ischemic reperfusion injury in cats.
Cardiovasc Res 1999;41:65-76.
10. Scalia R, Hayward R, Armstead VE, Minchenko AG, Lefer
AM. Effect of recombinant soluble P-selectin glycoprotein
ligand-1 on leukocyte-endothelium interaction in vivo. Role
in rat traumatic shock. Circulation Res 1999;84:93-102.
11. Dulkanchainun TS, Goss JA, Imagawa DK, Shaw GD,
Anselmo DM, Kaldas F, et al. Reduction of hepatic
ischemia/reperfusion injury by a soluble P-selectin glycopro-
tein ligand-1. Ann Surg 1998;227:832-40.
12. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney
NL. The cytokine-adhesion molecule cascade in
ischemia/reperfusion injury of the rat kidney. Inhibition by a
soluble P-selectin ligand. J Clin Invest 1997;99:2682-90.
13. Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism
between platelets and neutrophils in provoking cardiac dys-
function after ischemia and reperfusion: role of selectins.
Circulation 1998;98:1322-8.
14. Guyer DA, Moore KL, Lynam EB, Schammel CM, Rogelj S,
McEver RP, et al. P-selectin glycoprotein ligand-1 (PSGL-1)
is a ligand for L-selectin in neutrophil aggregation. Blood
1996;88:2415-21.
15. Strieter RM, Koch AE, Antony VB, Fick RB, Standiford TJ,
Kunkel SL. The immunopathology of chemotactic cytokines:
the role of interleukin-8 and monocyte chemoattractant pro-
tein-1. J Lab Clin Med 1994;123:183-97.
16. Kumar A, Villani MP, Patel UK, Keith JC, Schaub RG.
Recombinant soluble form of PSGL-1 accelerates thrombol-
ysis and prevents reocclusion in a porcine model. Circulation
1999;99:1363-9.
17. Toombs CF, DeGraaf GL, Martin JP, Geng JG, Anderson
DC, Shebuski RJ. Pretreatment with a blocking monoclonal
antibody to P-selectin accelerates pharmacological thrombol-
ysis in a primate model of arterial thrombosis. J Pharmacol
Exp Ther 1995;275:941-9.
18. Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C,
Hsu YM, et al. Leukocyte accumulation promoting fibrin
deposition is mediated in vivo by P-selectin on adherent
platelets. Nature 1992;359:848-51.
19. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie
BC, et al. P-selectin induces the expression of tissue factor on
monocytes. Proc Natl Acad Sci U S A 1994;91:8767-71.
20. Strieter RM, Kunkel SL. Acute lung injury: the role of
cytokines in the elicitation of neutrophils. J Investig Med
1994;42:640-51.
21. Yeo EL, Sheppard JA, Fuerstein IA. Role of P-selectin and
leukocyte activation in polymorphonuclear cell adhesion to sur-
face adherent activated platelets under physiologic shear condi-
tions (an injury vessel wall model). Blood 1994;83:2498-507.
22. Weyrich AS, McIntyre TM, McEver RP, Prescott SM,
Zimmerman GA. Monocyte tethering by P-selectin regulates
monocyte chemotactic protein-1 and tumor necrosis factor-
alpha secretion. Signal integration and NF-kappa B translo-
cation. J Clin Invest 1995;95:2297-303.
23. Murohara T, Parkinson SJ, Waldman SA, Lefer AM.
Inhibition of nitric oxide biosynthesis promotes P-selectin
expression in platelets. Role of protein kinase C. Arterioscler
Thromb Vasc Biol 1995;15:2068-75.
24. Celi A, Pellegrini G, Lorenzet R, De Blasi A, Ready N, Furie
BC, et al. P-selectin induces the expression of tissue factor on
monocytes. Proc Natl Acad Sci U S A 1994;91:8767-71.
25. Chen CC, Manning AA. Transcriptional regulation of
endothelial cell adhesion molecules: a dominant role for NF-
kappa B. Agents Actions 1995;47:135S-41S.
26. Weiser MR, Gibbs SA, Valeri CR, Shepro D, Hechtman HB.
Anti-selectin therapy modifies skeletal muscle ischemia and
reperfusion injury. Shock 1996;5:402-7.
27. Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder TF,
Clavien P-E. P-selectin mediates reperfusion injury through
neutrophil and platelet sequestration in the warm ischemic
mouse liver. Hepatology 1999;29:1494-502.
28. Jaeschke H. Is anti-P-selectin therapy effective in hepatic
ischemia-reperfusion injury because it inhibits neutrophil
recruitment? Shock 1999;12:233-4.
29. Zhang H, Schaub RG, Khor SP, Keith JC Jr, Kumar A. Anti-
thrombotic effect of a recombinant soluble P-selectin glyco-
protein ligand-1 chimera in a rat model of thrombosis
[abstract]. Circulation 1999;100(Suppl 1):I471.
30. Eppihimer MJ, Schaub RG. Effect of recombinant PSGL-I
(rPSGL-Ig) on vascular injury and thrombosis following
venous stasis [abstract]. Circulation 1999;100(Suppl 1)I812.
Submitted Jun 8, 1999; accepted Sep 21, 1999.
JOURNAL OF VASCULAR SURGERY
322 Wakefield et al February 2000
DISCUSSION
Dr Peter J. Pappas (Newark, NJ). To be a discussant
on a paper at The Society for Vascular Surgery meeting is
a great honor, but to review a well-performed investiga-
tion with clinical implications is an added bonus.
Dr Wakefield and his colleagues at the University of
Michigan have investigated the effect of a recombinant P-
selectin glycoprotein ligand-Ig (rPSGL-Ig) on clot resolu-
tion and thrombosis-induced inflammation. After the
induction of a caval thrombosis in baboons, the degree of
vein wall inflammation was analyzed with magnetic reso-
nance venography, morphometry for leukocyte invasion,
and enzyme-linked immunosorbent assays for interleukin-
8, monocyte chemotactic protein-1, and platelet factor IV.
Similar studies were performed to assess thrombus resolu-
tion. The authors noted less gadolinium enhancement of
the vena cava and the iliac veins with magnetic resonance
venography and decreased leukocyte and cytokine produc-
tion in the rPSGL-Ig group. 
Additionally, the rPSGL-Ig group was not associated
with alterations in coagulation parameters, indicating that
its effects were solely the result of its anti-inflammatory
properties.
I have several questions for the authors:
1. The authors assessed vein wall inflammation as the
degree of gadolinium enhancement in millimeters
squared. How were the intensity measurements stan-
dardized? For instance, when spectrophotometric mea-
surements are performed, as in your enzyme-linked
immunosorbent assays, several standards with known
intensities are measured and a standard curve is gener-
ated. In flow cytometry, beads with different bright-
nesses are measured and the machine is calibrated daily
to minimize day-to-day variations. Was the magnetic
resonance imaging calibrated against a known stan-
dard? If not, how was day-to-day variability mini-
mized? 
2. Does magnetic resonance venography enhancement
correlate with other known variables of vein wall
inflammation? In other words, with increased enhance-
ment, is an associated increase in leukocyte invasion
and tissue edema observed histologically? Has magnet-
ic resonance venography enhancement been validated
in other studies as an accurate measurement of vein
wall inflammation? 
3. Throughout the manuscript and, indeed, in your pre-
sentation today, you state that cytokine levels were
reduced in the rPSGL-Ig group despite equivalent
leukocyte numbers in the control and study groups. Is
this really an accurate statement? Interleukin-8, mono-
cyte chemotactic protein-1, and platelet factor IV were
not significantly different from controls at the inferior
vena cava level. Similarly, interleukin-8 was the only
cytokine reduction noted but, when adjusted for total
protein, was not significantly diminished when com-
pared with controls. My interpretation of the quanti-
tative vein wall morphometry and cytokine measure-
ments is that rPSGL-Ig does not affect leukocyte-
mediated invasion or cytokine production in the vein
wall, suggesting that rPSGL-Ig does not work by
inhibiting leukocyte activation. However, increased
clot resolution was clearly and unequivocally shown in
this group. Could an alternative mechanism for your
observations relate to inhibition of platelet-leukocyte
or platelet-endothelial interactions? As you stated in
the manuscript, P-selectin glycoprotein ligand causes
platelets to bind to leukocytes and endothelial cells
and P-selectin inhibition is associated with increased
thrombolysis. rPSGL-Ig may promote clot resolution
by preventing platelet degranulation, clot stabiliza-
tion, and vein wall inflammation rather than by affect-
ing leukocyte-mediated injury.
Finally, I would like to close by pointing out to the
audience that we have just been introduced to a new
class of drugs for the treatment of venous thrombo-
sis. The anti-inflammatory venous thrombotic drugs
offer numerous advantages over the currently avail-
able anticoagulants: (1) they have a half life of 15
days, suggesting that deep venous thrombosis can be
treated with biweekly outpatient visits rather than
daily warfarin sodium or low–molecular weight heparin
injections; (2) rPSGL-Ig does not adversely affect the
coagulation system, avoiding bleeding complications;
and (3) rPSGL-Ig directly attacks the venous thrombus
and possibly treats the venous endothelium as opposed
to the palliative effects of our current anticoagulants. 
I greatly enjoyed reading this manuscript and look
forward to the day when we can start using this new
class of drugs clinically. Thank you.
Dr Thomas W. Wakefield. Thank you. In answer to the
first question, we are measuring the area of enhancement
and not the intensity of enhancement. We are using clinical
software. The imaging parameters are constant from exam-
ination to examination, and the amount of gadolinium
administered is constant from examination to examination
and from animal to animal, so the technique is standardized. 
Secondly, magnetic resonance venography enhancement
has been used as a research tool in our laboratory in primates
and rats. We have also used it clinically in patients. In
patients, we published that the technique appears to differ-
entiate a thrombus less than 14 days old from one greater
than 14 days old. And in a rat study that used an anti-inflam-
matory cytokine interleukin-10, we validated the morpho-
metrics against the gadolinium enhancement.
And finally, concerning the mechanism, I do not total-
ly agree. The cytokines were decreased in the animals that
were administered the drug. The mechanism of inflamma-
tory inhibition does seem to be independent from simple
leukocyte extravasation. We know that this drug in other
studies inhibits leukocyte-leukocyte, leukocyte-platelet,
and leukocyte-platelet-endothelial cell interactions. In
addition, inflammatory cell activation may be inhibited by
the inhibition of P-selectin, and we also know that P-
selectin will stimulate the production of tissue factor from
monocytes. So, there are a number of other mechanisms
that probably come into play here, other than just the sim-
ple inhibition of leukocyte extravasation.
Dr Elliot L. Chaikof (Atlanta, Ga). Occasionally, when
protein-based drugs are administered repetitively on an
intravenous basis, antibodies can develop that can reduce
the effectiveness of the protein-based drug. Is this a
potential problem with this form of soluble P-selectin? Do
you see it reaching the clinical arena in this format? Or will
there eventually be other strategies directed towards P-
selectin blockade? 
Thank you.
Dr Jon S. Matsumura (Chicago, Ill). I am very inter-
ested in the use of this compound possibly for the patients
who are at high risk for hemorrhage, such as neurosurgi-
cal patients. Do you have any data or speculation regard-
ing the possible adverse effects the inflammatory blockade
may have on wound healing?
Dr Michael Sobel (Syracuse, NY). I enjoyed your
paper. I would like for you to speculate about how this
gives you some insights about the anti-inflammatory
effects of heparin, for example. Because, as I understand it,
native P-selectin glycoprotein ligand-Ig contains sulfated
oligosaccharides that are important for its function as a lig-
and or receptor, depending on what you want to call it.
And I think there is some evidence, actually, that heparin,
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like glycosaminoglycans, will interfere with this binding in
the same way that your pseudoligand P-selectin glycopro-
tein ligand-Ig does. Just some thoughts.
Dr Wakefield. As far as the clinical applicability, the
compound is in phase I studies, and clinical trials with this
compound are anticipated. Preclinical testing in animals
has not demonstrated that the effectiveness of the drug
decreases with multiple drug administrations.
We have seen no wound healing complications with
the drug in our model. And in work from the parent com-
pany for this compound, no wound healing complications
have been noted with its use. 
As far as the anti-inflammatory effects of heparin and
how this might relate, certainly we do not really under-
stand totally the mechanism of heparin’s anti-inflamma-
tory effects. Of interest, in some rat work in which we
have used a naturally occurring cytokine interleukin-10 to
inhibit inflammation and thrombosis, we have found that
when the drug is given systemically, both P-selectin and
E-selectin are decreased. So, the selectins have some
important role to play in both inflammation and throm-
bosis at initiation. And heparin, as shown by other investi-
gators, also has some inhibitory effects against P-selectin,
perhaps one of its anti-inflammatory mechanisms.
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